Current potential MS therapies
Research into new therapies is a lengthy process, but there is hope offered by some of the exciting new findings. A range of potential therapies for Multiple Sclerosis (MS) are working their way through the clinical trial pipeline at the moment.
Another class of drugs which are a focus in MS clinical trials are called monoclonal antibodies. These offer more favourable, substantially less frequent dosing routines compared with current MS therapies. The initial results look promising however they appear to be associated with specific and potentially serious side effects and safety concerns must be resolved before they are widely used to treat MS.
There are currently nearly 300 registered MS trials being carried out worldwide. These pages are designed to give you more information about the progress on current experimental treatments and clinical trials. They focus on the drugs which are in late stage phase III clinical trials and which should produce results before 2012.
For more information about which clinical trials are running for people with MS, ClinicalTrials.gov provides current information about each trial’s purpose, who may participate, locations, and phone numbers for more details. The information provided on ClinicalTrials.gov should be used in conjunction with advice from health care professionals.